Recorded fact · drug.label_indication
drug.label_indication for belzutifan|neuroendocrine-tumors
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 8c1c4cc9 resolves to.
The record
| Fact id | 8c1c4cc93f74b8161e7ac6c1 |
|---|---|
| Entity | drug: belzutifan|neuroendocrine-tumors |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260612 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: f4301fd81cb889ab65db0c514fb2fd3f861fba77a67a326f74a8a60a2371ac85.
The value
{
"ingredient": "Belzutifan",
"conditionId": "neuroendocrine-tumors",
"conditionName": "Neuroendocrine Tumors",
"matchedAlias": "neuroendocrine tumors",
"context": "indication",
"brand": "WELIREG",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "13e15ee0-d679-4fa9-9430-e2e2170474da",
"labelEffectiveTime": "20260612",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 2563ce933aaa5e3c434e5575c260355c7c4df6374fbb45ef6cab60548f405c15.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.